Navigation Links
Poniard Pharmaceuticals Appoints Gary A. Lyons to Board of Directors
Date:7/9/2009

pment, Vice President of Sales, and Director of Sales and Marketing. Mr. Lyons currently serves on the Boards of Directors for Rigel Pharmaceuticals, Inc., Vical, Incorporated, and Facet Biotech, all publicly held biotechnology companies. Mr. Lyons holds a B.S. in marine biology from the University of New Hampshire and a M.B.A. from Northwestern University's J.L. Kellogg Graduate School of Management.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and castration-resistant (hormone refractory) prostate cancers. The Company also is conducting a clinical trial of oral picoplatin in solid tumors. For additional information, please visit http://www.poniard.com.

Forward-Looking Statement

This release contains forward-looking statements, including statements regarding the Company's business objectives and strategic goals, drug development plans, the potential safety and efficacy of its products in development, and commercialization and partnering strategy. The Company's actual results may differ materially from those indicated in these forward-looking state
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Poniard Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
2. Poniard Pharmaceuticals Files Shelf Registration
3. Poniard Pharmaceuticals to Present at the Leerink Swann Oncology Roundtable Conference
4. Poniard Pharmaceuticals to Present at the 2009 BIO International Convention
5. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer
6. Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Researchs 100th Annual Meeting
7. Poniard Pharmaceuticals Reschedules Fourth Quarter and Fiscal 2008 Results Conference Call for Monday, March 16
8. Poniard Pharmaceuticals to Host Fourth Quarter and Year-End 2008 Financial Results Conference Call on March 12
9. Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer
10. Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference
11. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), ... development of autologous cell therapies, announced today the publication ... in conjunction with co-authors from Kyoto University and the ... ongoing clinical research using dermal sheath cup (DSC) cells ... The paper entitled " Hair Follicle Dermal Stem Cells ...
(Date:12/22/2014)... 2014 The American Journal ... original research, reviews and editorials addressing developments and ... today published a provocative article exploring the role ... and potential treatment of prostate cancer. , ... proposes the possibility that there could be a ...
(Date:12/19/2014)... Charm Sciences is pleased to announce that its ... M1 in raw commingled milk is the first lateral ... peer reviewed report of the validation by Technology and ... Fisheries Research (ILVO-T&V) has been published by the Taylor ... toxic aflatoxin and a known carcinogen, can be passed ...
(Date:12/19/2014)... CITY, Calif. , Dec. 19, 2014 Bina ... , USA) announced today that they have been acquired ... 1,2 is a privately held company that provides ... of next generation sequencing (NGS) data for the academic ... the Roche Sequencing Unit, and will continue to focus ...
Breaking Biology Technology:Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... image of the carotid arteries that supply blood to the ... of Michigan Health System are using the system to diagnose ... Wire. Milwaukee GE Healthcare ... give physicians a non-invasive view of the heart and blood ...
... Finance Committee rejected Governor Jim Doyle's proposal for a 5 ... a plan to charge consumers for their music, book, art, ... turned down by the budget review panel. , ,After much ... entertainment called by some detractors the "iPod tax" ...
... your card in an ATM in San Francisco, the system ... But if you find yourself in an emergency room you'll ... series of tests because your medical record is a piece ... technology baffles users with ever-growing capabilities, including instant global transfer ...
Cached Biology Technology:GE Healthcare launches new medical scanner, places another in hospitals 2GE Healthcare launches new medical scanner, places another in hospitals 3Finance Committee rejects extra tax on Internet buys 2Finance Committee rejects extra tax on Internet buys 3Physician mindset slows adoption of electronic health records 2Physician mindset slows adoption of electronic health records 3Physician mindset slows adoption of electronic health records 4
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... to their offering. One major ... of multimodal biometric systems. Multimodal biometric systems utilize ... verification and identification purposes. This helps to reduce ...
(Date:12/11/2014)... 10, 2014  Data Sciences International (DSI), the ... a new series of digital telemetry implants to ... M series, part of the PhysioTel™ Digital platform, ... possible physiologic data when incorporating functional endpoints into ... to toxicology studies has evolved from short ECG ...
(Date:12/10/2014)... 9, 2014  Valencell, a leader in performance biometric ... staggering demand from its licensees for highly accurate, clinically ... not solely coming from fitness and health sectors, but ... "A wearable is only as useful as the biometric ... ultimate driver in long-term mass consumer adoption of wearable ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... cancer,has been announced by Agilent Technologies. The company ... advance of microarray-based,comparative genomic studies in cancer. According ... issue of the Proceedings of the,National Academy of ... Research Institute, Agilent has developed a specialised,microarray platform ...
... in life science and drug development : only "lucrative","markets" ... very promising drugs candidates or related research get canned,because ... if millions would have,been saved worldwide. The usual strategy ... that affect a "profitable" disease in addition to the,"non-profitable" ...
... "nano" - cancer detection using nanoparticles and MRI (magnetic ... one of the most important parts of the,work up ... the most appropriate treatment. And an essential part of ... been lymphatic spread. Current,methods include surgical removal of nodes ...
Cached Biology News:Breakthrough Microarray-based Technology for the Study of Cancer 2Finding Cures For Tropical Diseases: Is Open Source An Answer? 2Imaging Lymph Nodes with Nanoparticles 2
... 2D polyacrylamide gel electrophoresis (2D-PAGE) with biological ... core technology platform for proteomic analysis. 2D-PAGE ... samples limited only in the dynamic range ... proteins. Quantitative image based analysis of separated ...
... recombinant 177 amino acid polypeptide sequence corresponding ... MT1-MMP. Produced by activation of a ... E. coli periplasm. SPECIFIC ACTIVITY:The specific ... 140 mU/mg, where 1 U is the ...
Human interferon-beta (IFN-beta). Recognizes amino acids 30-47 of IFN-beta. No cross-reactivity with Human IFN-alpha or IFN-gamma....
Acetate Plate Sealers 100/Box...
Biology Products: